
Kriya Therapeutics: Pioneering gene therapies for global health challenges in ophthalmology, neurology, and metabolism.
Kriya Therapeutics is a biopharmaceutical company focused on developing gene therapies for diseases impacting millions globally. With a presence in Palo Alto, California, and Research Triangle Park, North Carolina, Kriya targets ophthalmology, neurology, and metabolic diseases. The company has raised over $450 million to support its mission of transforming gene therapy.
Kriya Therapeutics has made significant strides in advancing its gene therapy pipeline, addressing critical health challenges. The company's innovative approach and substantial funding have positioned it as a leader in the biopharmaceutical industry, driving progress in treating complex diseases.
Similar Company · Competitor

Alchemab Therapeutics
Similar Company · Competitor

Numerion Labs

Krystal Biotech
krystalbio.com

Poseida Therapeutics
poseida.com

Nephrogen

Voyager Therapeutics

Jaguar Gene Therapy

Excision BioTherapeutics

Kymera Therapeutics
kymeratx.com

bluebird bio
bluebirdbio.com

Castle Creek Biosciences
castlecreekbio.com

Denali Therapeutics

Forge Biologics
forgebiologics.com

4D Molecular Therapeutics

Taysha Gene Therapies
tayshagtx.com

Code Biotherapeutics
codebiotx.com
Triplet Therapeutics
triplettx.com

Nanoscope Therapeutics

Regel Therapeutics

RainBio
rainbio.us
Companies similar to Kriya Therapeutics include Alchemab Therapeutics, Numerion Labs, Krystal Biotech and Poseida Therapeutics.
Kriya Therapeutics was founded in 2019.
Kriya Therapeutics' headquarters is located in Morrisville, NC, US.
Kriya Therapeutics' most recent funding round was for $320M (USD) in September 2025.
As of Sep 10, 2025, Kriya Therapeutics has disclosed funding of $920.5M (USD).
Kriya Therapeutics has 194 employees as of Feb 5, 2024.